

COVAX AMC SUPPORT TO INDIA

BOARD MEETING

Homero Hernandez, SCM India

15-17 December 2020, Virtual Meeting



Reach every child

www.gavi.org

Background


- India is part of the COVAX AMC92 and Gavi 57* eligible countries, yet requires a tailored approach
- The highest-burden Gavi supported country and currently the second-most affected in the world with over 9.7 million confirmed cases
- The worst affected emerging economy and one of the worst affected AMC92 economies by far
- Low-income and vulnerable populations heavily affected
- While tremendous efforts have been made to recover coverage level since June, routine immunisation severely affected with significant declines in the initial phase of the lockdown, (-50% DTP3) during the month of April
- Government of India has stated and reiterated their solidarity and commitment to provide domestic production of vaccines to COVAX and the rest of the world, as stated by Prime Minister Modi

*Part of the original 57 eligible Gavi countries, but having a tailored strategy and level of support

**Board meeting
15-17 December 2020**




India's tailored approach takes into account...



India's population size, disease burden and related mortality, subnational inequities and economic impact



India's global vaccine manufacturing capacity and a critical supplier to COVAX



The ability of the AMC91 economies to vaccinate the aspirational 20% of their population

Board meeting
15-17 December 2020

India's COVID-19 vaccines roll-out plan

India plans on using
~600 million COVID-19
vaccine doses to
reach ~23% of their
prioritised population

- 1 Targeting 10 million frontline health workers by February 2021
- 2 Targeting 20 million frontline and essential workers by March 2021
- 3 Targeting 270 million general population above 50 years of age including persons below 50 years of age with co-morbidities by August 2021

- Government of India has submitted Technical Assistance and Cold Chain Equipment (CCE) applications for COVAX support > US\$ 30 million for urgent planning, preparedness and COVID-19 vaccine roll-out
- Government is also in discussion with private sector logistics companies for ensuring vaccines reach beneficiaries targeted

Board meeting
15-17 December 2020



Scenarios for COVAX donor-funded doses



Pro-rata share of
35% of donor-
funded doses



10% of AMC
doses



20%
of AMC doses

- **To reach the aspirational equitable goal** of the COVAX Facility, India should receive 35% of donor-funded doses
- Given the current information on resources mobilised and estimated vaccine prices, this option is currently not viable for the COVAX Facility to reach its goal
- **10% of AMC level of support** would mean that India receives AMC doses equivalent to the next most populous AMC92 economy despite having five times its population and higher disease burden.
- This **minimum level of support** would **cover ~3-5% of India's population**, creating high disparity with other AMC countries that would receive doses to cover ~17-22% of population.
- **Protects sufficient doses** and funding to allow AMC91 economies to cover ~15-20% of their population (*subject to vaccine prices and fundraising*)
- **Minimise the disparity in population coverage** from AMC doses between India and other AMC economies



RECOMMEND

Board meeting
15-17 December 2020



Scenarios for COVAX TA and CCE support



10%
of AMC TA
and CCE



20%
of AMC TA
and CCE

- Allocating US\$ 15 million (10% of AMC TA and CCE envelop) would mean that India would not be able to fill in gaps for urgent TA and CCE needs
 - Currently expressed needs for TA are > US\$ 27 million and for CCE > US\$ 8 million
-
- Allocating US\$ 30 million (20% of AMC TA and CCE envelop) would protect sufficient funding to allow AMC91 countries to cover urgent needs estimated
 - This allocation would minimise risks and enable India to fill gaps in resources urgently needed to successfully rollout COVID-19 vaccines in early 2021



RECOMMEND

Board meeting
15-17 December 2020

Recommendation

The Gavi Alliance Board is requested to:

Approve the proposed (high range) package of support for India as described in Annex A to Doc 10 providing 20% of total AMC doses to cover approximately 7-9% of India's population and 20% of the overall amount provided for urgent TA and Cold Chain Equipment (CCE).



Reach every child
www.gavi.org